China Natural Product Research Manufacturers & Supplier

Unlike brokers or bulk extract suppliers, an integrated research CRO/CDMO like MedGence (Yineng Pharma) provides scientific validation, de novo extraction process engineering, validated HPLC/HPTLC analytical assays, in vitro cell studies, animal toxicity safety dossiers, and Phase I–IV clinical development. We function as your contracted laboratory and pilot facility to deliver regulatory packages and proprietary compounds.

We address seasonal and geographical variations by standardizing harvest regions and monitoring multi-compound chemical profiles across different seasons. Using dual HPLC and HPTLC fingerprint overlays, continuous countercurrent extraction, and resin fraction blending, we ensure that every batch of active components aligns with strict identity and potency specifications.

All research and contract manufacturing programs operate under legally binding NDAs and contract research frameworks. MedGence preserves customer trade secrets, custom formula parameters, and extraction conditions in closed-loop server architectures, guaranteeing that the intellectual property generated remains exclusively yours.

We supply intermediate actives as concentrated liquids, spray-dried water-soluble powders, purified pastes, and volatile essential oils. Finished product manufacturing capabilities cover hard-shell capsules, softgels, micro-tablets, enteric-coated formats, oral functional liquids, and effervescent granules.

Yes. Our preclinical and clinical research infrastructure supports Phase I–IV clinical studies, formal GLP toxicity evaluation (acute, chronic, genotoxicity, and teratogenicity), CMC batch characterizations, and pharmacokinetic studies designed to meet the expectations of China's NMPA, US FDA, and global regulatory bodies.